ROIVANT SCIENCES LTD. Gain (Loss) on Investments
ROIVANT SCIENCES LTD. (ROIV) reported Gain (Loss) on Investments of $36.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnInvestments · last filed 2026-08-06
- ROIVANT SCIENCES LTD. gain (loss) on investments for the quarter ending 2026-06-30 was $36.64M.
- ROIVANT SCIENCES LTD. gain (loss) on investments for the quarter ending 2026-03-31 was -$25.92M, a 300.96% decline year-over-year.
- ROIVANT SCIENCES LTD. gain (loss) on investments for the quarter ending 2025-12-31 was $21.59M.
- ROIVANT SCIENCES LTD. gain (loss) on investments for the quarter ending 2025-09-30 was $128.50M, a 165.64% increase year-over-year.
- ROIVANT SCIENCES LTD. gain (loss) on investments for fiscal 2026 was $105.05M, a 90.35% increase from fiscal 2025.
- ROIVANT SCIENCES LTD. gain (loss) on investments for fiscal 2025 was $55.19M.
- ROIVANT SCIENCES LTD. gain (loss) on investments for fiscal 2024 was -$47.97M.
- ROIVANT SCIENCES LTD. gain (loss) on investments for fiscal 2023 was -$20.82M.
| Period end | Gain (Loss) on Investments 3 month | Gain (Loss) on Investments 6 month | Gain (Loss) on Investments 9 month | Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $36.64M 10-Q · filed 2026-08-06 | $10.71M derived: sum of 2 quarters · filed 2026-08-06 | $32.31M derived: sum of 3 quarters · filed 2026-08-06 | $160.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$25.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$4.33M derived: sum of 2 quarters · filed 2026-05-20 | $124.17M derived: sum of 3 quarters · filed 2026-05-20 | $105.05M 10-K · filed 2026-05-20 |
| 2025-12-31 | $21.59M 10-Q · filed 2026-02-06 | $150.09M derived: sum of 2 quarters · filed 2026-02-06 | $130.97M 10-Q · filed 2026-02-06 | $143.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | $128.50M 10-Q · filed 2025-11-10 | $109.38M 10-Q · filed 2025-11-10 | $122.28M derived: sum of 3 quarters · filed 2026-08-06 | $100.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$19.13M 10-Q · filed 2026-08-06 | -$6.23M derived: sum of 2 quarters · filed 2026-08-06 | -$27.54M derived: sum of 3 quarters · filed 2026-08-06 | $20.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $12.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$8.41M derived: sum of 2 quarters · filed 2026-05-20 | $39.96M derived: sum of 3 quarters · filed 2026-05-20 | $55.19M 10-K · filed 2026-05-20 |
| 2024-12-31 | -$21.31M 10-Q · filed 2026-02-06 | $27.06M derived: sum of 2 quarters · filed 2026-02-06 | $42.29M 10-Q · filed 2026-02-06 | $58.19M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | $48.38M 10-Q · filed 2025-11-10 | $63.60M 10-Q · filed 2025-11-10 | $79.51M derived: sum of 3 quarters · filed 2026-05-20 | $69.04M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | $15.23M 10-Q · filed 2025-08-11 | $31.13M derived: sum of 2 quarters · filed 2026-05-20 | $20.67M derived: sum of 3 quarters · filed 2026-05-20 | -$25.18M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | $15.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $5.44M derived: sum of 2 quarters · filed 2026-05-20 | -$40.41M derived: sum of 3 quarters · filed 2026-05-20 | -$47.97M 10-K · filed 2026-05-20 |
| 2023-12-31 | -$10.47M 10-Q · filed 2025-02-10 | -$56.32M derived: sum of 2 quarters · filed 2025-02-10 | -$63.88M 10-Q · filed 2025-02-10 | -$31.42M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | -$45.85M 10-Q · filed 2024-11-12 | -$53.41M 10-Q · filed 2024-11-12 | -$20.95M derived: sum of 3 quarters · filed 2025-05-29 | $5.00M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | -$7.56M 10-Q · filed 2024-08-09 | $24.90M derived: sum of 2 quarters · filed 2025-05-29 | $50.85M derived: sum of 3 quarters · filed 2025-05-29 | -$3.83M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | $32.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $58.41M derived: sum of 2 quarters · filed 2025-05-29 | $3.73M derived: sum of 3 quarters · filed 2025-05-29 | -$20.82M 10-K · filed 2025-05-29 |
| 2022-12-31 | $25.95M 10-Q · filed 2024-02-13 | -$28.73M derived: sum of 2 quarters · filed 2024-02-13 | -$53.28M 10-Q · filed 2024-02-13 | -$126.19M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | -$54.68M 10-Q · filed 2023-11-13 | -$79.22M 10-Q · filed 2023-11-13 | -$152.13M derived: sum of 3 quarters · filed 2023-11-13 | -$190.17M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$24.55M 10-Q · filed 2023-08-14 | -$97.46M derived: sum of 2 quarters · filed 2023-08-14 | -$135.49M derived: sum of 3 quarters · filed 2023-08-14 | -$103.22M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$72.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | -$110.94M derived: sum of 2 quarters · filed 2023-06-28 | -$78.67M derived: sum of 3 quarters · filed 2023-06-28 | -$87.29M 10-K · filed 2023-06-28 |
| 2021-12-31 | -$38.04M 10-Q · filed 2023-02-13 | -$5.76M derived: sum of 2 quarters · filed 2023-02-13 | -$14.38M 10-Q · filed 2023-02-13 | -$26.06M derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-09-30 | $32.27M 10-Q · filed 2022-11-14 | $23.65M 10-Q · filed 2022-11-14 | $11.98M derived: sum of 3 quarters · filed 2022-11-14 | -$6.26M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$8.62M 10-Q · filed 2022-08-15 | -$20.30M derived: sum of 2 quarters · filed 2022-08-15 | -$38.53M derived: sum of 3 quarters · filed 2022-08-15 | $45.77M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$11.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | -$29.91M derived: sum of 2 quarters · filed 2022-06-28 | $54.38M derived: sum of 3 quarters · filed 2022-06-28 | $95.53M 10-K · filed 2022-06-28 |
| 2020-12-31 | -$18.23M 10-Q · filed 2022-02-14 | $66.06M derived: sum of 2 quarters · filed 2022-02-14 | $107.21M 10-Q · filed 2022-02-14 | |
| 2020-09-30 | $84.30M 10-Q · filed 2021-11-15 | $125.44M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $41.15M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |